GlassScriptPhysician profile
Scott Robert Boerth
NPI 1366439721
$8,346.99
in general payments reported to CMS, 2019-2025
51 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $1,592 · 2021: $1,797 · 2022: $1,168 · 2023: $1,301 · 2024: $864 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568 · Gift: $59.40 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.98 |
| Gift | $59.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,483.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $870.59 | 2019-2024 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $850.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $714.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $546.86 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $366.10 | 2019-2020 | |
| Mannkind Corporation | $346.71 | 2020-2023 | Afrezza |
| Pfizer INC. | $256.62 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $221.81 | 2020-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.65 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $189.15 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $178.54 | 2021-2025 | |
| Amgen INC. | $176.99 | 2021-2024 | Evenity, Prolia, Amjevita |
| Bausch Health US, LLC | $174.54 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Boerth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.